

Express Mail Label EV 057 398 219 US

Attorney Docket No. 50450-8025.US01

I hereby certify that this correspondence is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 addressed to the Assistant Commissioner for Patents, Box CPA, Washington, D.C., 20231, on:

Date: 8-15-02By: Vanessa Sanchez

AUG 22 2002

TECH CENTER 1600/2900  
PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Iversen, et al.

APPLICATION NO.: 09/493,427

FILED: January 29, 2000

FOR: ANTISENSE RESTENOSIS COMPOSITION  
AND METHOD

EXAMINER: Epps. J.

ART UNIT: 1635

#15/ R.T.  
8/24  
Pre  
CPreliminary Amendment

Box CPA  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Before examination of the above-referenced continuation application, filed herewith, please amend the application as set forth below. A petition for a 5 month extension of time and the required fee pursuant to 37 C.F.R. §1.17(a)(2), as required to keep the parent application (US Patent Application S/N 09/493,427) pending is included herewith.

In the Claims:

Please cancel claims 23-27 without prejudice and add new claims 28-48 as follows:

28. A method for treating a vascular injury site by reducing restenosis at the site, said method comprising

administering to a patient, by intravascular delivery directly to the vascular injury site, a morpholino antisense compound having (i) from 8 to 40 nucleotides, including a targeting base sequence that is complementary to a region that spans the start codon of a human *c-myc* mRNA gene, and (ii) uncharged, phosphorous-containing intersubunit linkages, in an amount effective to reduce restenosis in the patient.

{09901-0001/BY022260.C62}